2018
DOI: 10.1016/j.phrs.2018.03.013
|View full text |Cite
|
Sign up to set email alerts
|

Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
65
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 116 publications
(82 citation statements)
references
References 66 publications
2
65
0
Order By: Relevance
“…Latest information on various preclinical and clinical anticancer trials using curcumin is reviewed in Doello et al (2018). Recently, in patients with locally advanced or metastatic pancreatic cancer, curcumin Meriva ® (2,000 mg/day) in complementary to gemcitabine was found to increase the efficacy of gemcitabine without any treatment-related toxicity (Pastorelli et al, 2018). Currently, a randomized, double-blind, placebo-controlled phase 2/3 trial is ongoing to determine the efficacy of curcumin (300 mg/i.v./day) along with Paclitaxel (80 mg/m2 BS; i.v.)…”
Section: Phytochemicals Evaluated In Clinical Trialsmentioning
confidence: 99%
“…Latest information on various preclinical and clinical anticancer trials using curcumin is reviewed in Doello et al (2018). Recently, in patients with locally advanced or metastatic pancreatic cancer, curcumin Meriva ® (2,000 mg/day) in complementary to gemcitabine was found to increase the efficacy of gemcitabine without any treatment-related toxicity (Pastorelli et al, 2018). Currently, a randomized, double-blind, placebo-controlled phase 2/3 trial is ongoing to determine the efficacy of curcumin (300 mg/i.v./day) along with Paclitaxel (80 mg/m2 BS; i.v.)…”
Section: Phytochemicals Evaluated In Clinical Trialsmentioning
confidence: 99%
“…To address the low bioavailability of curcumin, a recent clinical trial investigated the combination of phospholipid-coated curcumin using nanotechnology and gemcitabine (111). Although the patient quality of life was not significantly improved during treatment, the patient drug response rate reached 27.3%, which was higher compared with the rate of 12% of gemcitabine alone, and the average progression-free survival and overall survival also reached 8.4 and 10.2 months, respectively (111).…”
Section: Recent Clinical Trials On Curcuminmentioning
confidence: 99%
“…To address the low bioavailability of curcumin, a recent clinical trial investigated the combination of phospholipid-coated curcumin using nanotechnology and gemcitabine (111). Although the patient quality of life was not significantly improved during treatment, the patient drug response rate reached 27.3%, which was higher compared with the rate of 12% of gemcitabine alone, and the average progression-free survival and overall survival also reached 8.4 and 10.2 months, respectively (111). Therefore, curcumin combined with gemcitabine is may be a safe and effective therapy for wider application for pancreatic cancer treatment; however, before the combination of curcumin and gemcitabine therapy can become routine therapy for pancreatic cancer large multicentric randomized controlled trials need to be conducted.…”
Section: Recent Clinical Trials On Curcuminmentioning
confidence: 99%
“…48 This same mechanism (a dissociation of the raptor protein from mTOR) is also responsible for rapamycin's inhibitory effects. 49 While numerous clinical trials have been conducted on curcumin supplementation, demonstrating anti-inflammatory or anticancer effects, [50][51][52][53][54][55][56] no human trials investigating a direct effect of curcumin on mTOR have been performed.…”
Section: Curcuminmentioning
confidence: 99%